Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates

Peter Thornton, Hachemi Kadri, Ageo Miccoli, Youcef Mehellou

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)
264 Downloads (Pure)

Abstract

Nucleoside monophosphates and monophosphonates have been known for a long time to exert favorable pharmacological effects upon intracellular delivery. However, their development as drug molecules has been hindered by the inherent poor druglike properties of the monophosphate and monophosphonate groups. These include inefficient cellular uptake and poor in vivo stability, with this latter drawback being most relevant to monophosphates than monophosphonates. To address these limitations, numerous monophosphate and monophosphonate prodrug strategies have been developed and applied in the discovery of nucleoside monophosphate and monophosphonate prodrugs that can treat viral infections and cancer. The approval of sofosbuvir, a nucleoside monophosphate prodrug, highlighted the success to be had by employing these prodrug technologies in the discovery of nucleotide therapeutics. In this Miniperspective, we discuss the different key monophosphate and monophosphonate nucleoside prodrugs that entered clinical development, some of which may in the future be approved to treat various human diseases.
Original languageEnglish
JournalJournal of Medicinal Chemistry
Early online date25 Aug 2016
DOIs
Publication statusE-pub ahead of print - 25 Aug 2016

Fingerprint

Dive into the research topics of 'Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates'. Together they form a unique fingerprint.

Cite this